Richard C. Young & CO. LTD. Has $8.48 Million Holdings in Sanofi SA (NYSE:SNY)

Richard C. Young & CO. LTD. boosted its holdings in shares of Sanofi SA (NYSE:SNY) by 1.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 195,964 shares of the company’s stock after buying an additional 2,126 shares during the quarter. Sanofi makes up approximately 1.6% of Richard C. Young & CO. LTD.’s investment portfolio, making the stock its 28th largest position. Richard C. Young & CO. LTD.’s holdings in Sanofi were worth $8,479,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. NumerixS Investment Technologies Inc increased its position in Sanofi by 218.8% during the first quarter. NumerixS Investment Technologies Inc now owns 17,800 shares of the company’s stock worth $788,000 after buying an additional 12,216 shares during the last quarter. Ibex Wealth Advisors acquired a new position in Sanofi during the second quarter worth approximately $25,000. CENTRAL TRUST Co increased its position in Sanofi by 18.4% during the second quarter. CENTRAL TRUST Co now owns 7,027 shares of the company’s stock worth $298,000 after buying an additional 1,092 shares during the last quarter. Dearborn Partners LLC acquired a new position in Sanofi during the second quarter worth approximately $251,000. Finally, Atlas Capital Advisors LLC acquired a new position in Sanofi during the second quarter worth approximately $164,000. 7.04% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Sanofi stock traded up $0.03 on Friday, hitting $42.60. The stock had a trading volume of 14,028 shares, compared to its average volume of 1,239,604. Sanofi SA has a twelve month low of $40.00 and a twelve month high of $45.62. The business’s 50 day moving average is $42.10 and its two-hundred day moving average is $42.60. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The stock has a market cap of $106.87 billion, a price-to-earnings ratio of 13.62, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67.

Sanofi (NYSE:SNY) last posted its earnings results on Monday, July 29th. The company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.67 by $0.07. The company had revenue of $8.63 billion for the quarter, compared to the consensus estimate of $8.42 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.25 earnings per share. As a group, equities analysts predict that Sanofi SA will post 3.1 earnings per share for the current fiscal year.

Several equities analysts have recently commented on the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Tuesday, August 6th. UBS Group raised Sanofi from a “neutral” rating to a “buy” rating in a research report on Wednesday, August 14th. Finally, TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research report on Friday, June 21st. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $51.00.

In related news, major shareholder Sanofi purchased 93,750 shares of the business’s stock in a transaction that occurred on Monday, July 22nd. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $1,500,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.00% of the company’s stock.

Sanofi Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Further Reading: What is Call Option Volume?

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.